The successful remission induction by sorafenib and long-term complete remission in a FLT3-ITD-positive patient with a refractory acute erythroid leukemia and abnormal cytogenetics-Reference-Cited by-同舟云学术

The successful remission induction by sorafenib and long-term complete remission in a FLT3-ITD-positive patient with a refractory acute erythroid leukemia and abnormal cytogenetics

Published:2012-01 Issue:1 Volume:36 Page:e1-e3
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Mori Masanori,Sprague Julian

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference10 articles.

1. The role of FLT3 in haematopoietic malignancies;Stirewalt;Nat Rev Cancer,2003

2. Acute myeloid leukaemia with recurrent genetic abnormalities;Arber,2008

3. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461);Byrd;Blood,2002

4. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis;Thlede;Blood,2002

5. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia;Zhang;J Natl Cancer Inst,2008

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Carbon 21 Steroidal Glycoside with Pregnane Skeleton from Cynanchum atratum Bunge Promotes Megakaryocytic and Erythroid Differentiation in Erythroleukemia HEL Cells through Regulating Platelet-Derived Growth Factor Receptor Beta and JAK2/STAT3 Pathway;Pharmaceuticals;2024-05-14

2. Prognosis and outcome of patients with acute myeloid leukemia based on FLT3‑ITD mutation with or without additional abnormal cytogenetics;Oncology Letters;2019-11-05

3. Precision therapy for acute myeloid leukemia;Journal of Hematology & Oncology;2018-01-05

4. Diagnosis and Prognosis: Molecular;Myelodysplastic Syndromes;2018

5. Morphology and Flow Cytometry;Myelodysplastic Syndromes;2018